Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hayley C Whitaker

Showing results (31-40 of 67) with videos related to

Pageof 7
Sort By:
Urology|December 5, 2020
Prostate Cancer Undetected by mpMRI: Tumor Conspicuity is Reliant Upon Optimal Scan Timing and QualityJoseph M Norris, Clare Allen, Rhys Ball, et al.
Journal of Robotic Surgery|April 13, 2022
Diagnostic potential of radiological apical tumor involvementCasril Liebert, Naomi Morka, Pranav Satish, et al.
BJU International|November 13, 2020
Conspicuity of cribriform prostate cancer on multiparametric magnetic resonance imaging: the jury is still outJoseph M Norris, Lina M Carmona Echeverria, Benjamin S Simpson, et al.
European Urology Open Science|August 2, 2021
Which Prostate Cancers are Undetected by Multiparametric Magnetic Resonance Imaging in Men with Previous Prostate Biopsy? An Analysis from the PICTURE StudyJoseph M Norris, Lucy A M Simmons, Abi Kanthabalan, et al.
BMJ Open|January 30, 2020
Genetic landscape of prostate cancer conspicuity on multiparametric MRI: a protocol for a systematic review and bioinformatic analysisJoseph M Norris, Benjamin S Simpson, Marina A Parry, et al.
BJU International|October 11, 2019
Genetic correlates of prostate cancer visibility (and invisibility) on multiparametric magnetic resonance imaging: it's time to take stockJoseph M Norris, Benjamin S Simpson, Marina A Parry, et al.
BJU International|April 23, 2020
Prostate cancer visibility on multiparametric magnetic resonance imaging: high Gleason grade and increased tumour volume are not the only important histopathological featuresJoseph M Norris, Lina M Carmona Echeverria, Benjamin S Simpson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 3, 2011
Engrailed-2 (EN2): a tumor specific urinary biomarker for the early diagnosis of prostate cancerRichard Morgan, Angela Boxall, Aagna Bhatt, et al.
British Journal of Cancer|February 3, 2017
Asporin is a stromally expressed marker associated with prostate cancer progressionAnnie Rochette, Nadia Boufaied, Eleonora Scarlata, et al.
Molecular Endocrinology (Baltimore, Md.)|August 18, 2012
Role of the HSP90-associated cochaperone p23 in enhancing activity of the androgen receptor and significance for prostate cancerVikash Reebye, Laia Querol Cano, Derek N Lavery, et al.
Pageof 7

Showing results (31-40 of 67) with videos related to

Sort By:
Pageof 7
Urology|December 5, 2020
Prostate Cancer Undetected by mpMRI: Tumor Conspicuity is Reliant Upon Optimal Scan Timing and QualityJoseph M Norris, Clare Allen, Rhys Ball, et al.
Journal of Robotic Surgery|April 13, 2022
Diagnostic potential of radiological apical tumor involvementCasril Liebert, Naomi Morka, Pranav Satish, et al.
BJU International|November 13, 2020
Conspicuity of cribriform prostate cancer on multiparametric magnetic resonance imaging: the jury is still outJoseph M Norris, Lina M Carmona Echeverria, Benjamin S Simpson, et al.
European Urology Open Science|August 2, 2021
Which Prostate Cancers are Undetected by Multiparametric Magnetic Resonance Imaging in Men with Previous Prostate Biopsy? An Analysis from the PICTURE StudyJoseph M Norris, Lucy A M Simmons, Abi Kanthabalan, et al.
BMJ Open|January 30, 2020
Genetic landscape of prostate cancer conspicuity on multiparametric MRI: a protocol for a systematic review and bioinformatic analysisJoseph M Norris, Benjamin S Simpson, Marina A Parry, et al.
BJU International|October 11, 2019
Genetic correlates of prostate cancer visibility (and invisibility) on multiparametric magnetic resonance imaging: it's time to take stockJoseph M Norris, Benjamin S Simpson, Marina A Parry, et al.
BJU International|April 23, 2020
Prostate cancer visibility on multiparametric magnetic resonance imaging: high Gleason grade and increased tumour volume are not the only important histopathological featuresJoseph M Norris, Lina M Carmona Echeverria, Benjamin S Simpson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 3, 2011
Engrailed-2 (EN2): a tumor specific urinary biomarker for the early diagnosis of prostate cancerRichard Morgan, Angela Boxall, Aagna Bhatt, et al.
British Journal of Cancer|February 3, 2017
Asporin is a stromally expressed marker associated with prostate cancer progressionAnnie Rochette, Nadia Boufaied, Eleonora Scarlata, et al.
Molecular Endocrinology (Baltimore, Md.)|August 18, 2012
Role of the HSP90-associated cochaperone p23 in enhancing activity of the androgen receptor and significance for prostate cancerVikash Reebye, Laia Querol Cano, Derek N Lavery, et al.
Pageof 7